Treatment of Alzheimer's disease: Future directions

Acta Neurologica Scandinavica

Volumn 94, Issue SUPPL.165, 1996, Pages 128-136

  Wilcock, G K ^a   Harrold, P L ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid; Nerve growth factor; Neurofibrillary tangle; Pharmacotherapy; Tacrine

Indexed keywords

ANTIINFLAMMATORY AGENT; ARECOLINE; AZATHIOPRINE; CHLOROQUINE; CHOLINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLONIDINE; CYCLOPHOSPHAMIDE; CYCLOSERINE; DAPSONE; DONEPEZIL; GALANTAMINE; IMMUNOMODULATING AGENT; INDOMETACIN; METHOTREXATE; METRIFONATE; MILACEMIDE; NERVE GROWTH FACTOR; NEUROTROPHIN; NICOTINE; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; RISPERIDONE; SELEGILINE; TACRINE; TRAZODONE; UNINDEXED DRUG; VELNACRINE;

ALZHEIMER DISEASE; CONFERENCE PAPER; DEMENTIA; DRUG DEVELOPMENT; HUMAN; FORECASTING; REVIEW;

ALZHEIMER DISEASE; FORECASTING; HUMANS;

EID: 0029687083     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1996.tb05883.x     Document Type: Article

References (85)

1. Wilcock GK, Esiri MM. Plaques, tangles and dementia: a quantitative study. J Neurol Sci 1982: 56: 343-56.
2. Wilcock GK, Esiri MM, Bowen DM, Smith CCT. Alzheimer's disease: correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982: 57: 407-17.
3. Levy R., Little A., Chuagui P., Reith M. Early results from double-blind, placebo controlled trial of high dose phosphatidylcholine. Lancet 1983: 1: 987-88.
4. Graves AB, Van-Duijn CM, Chandra V. et al. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative reanalysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991: 20 Suppl 2: S48-S57.
5. Davis KL, Mohs RC, Tinklenberg JR. Enhancement of memory by physostigmine [letter]. N Engl J Med 1979: 301: 946.
6. Johns CA, Hartoutunian V., Greenwald BS et al. Development of cholinergic drugs for the treatment of Alzheimer's disease. Drug Dev Res 1985: 5: 77-96.
7. Elble RJ, Giacobini E., Becker R. et al. Treatment of Alzheimer dementia with steady-state infusion of physostigmine. In: Giacobini E., Becker R., eds. Current research in Alzheimer therapy: cholinesterase inhibitors. New York: Taylor & Francis, 1988: 123-39.
8. Gustafson L. Physostigmine and tetrahydroaminoacridine of Alzheimer's disease. Acta Neurol Scand Suppl 1993: 149: 39-41.
9. Peters BH, Levin HS. Chronic oral physostigmine and lecithin administration in memory disorders of aging. In: Corkin S., Davis KL, Growdon JH, Usdin E., Wurtman RJ, eds. Alzheimer's disease: a report of progress in research. Aging, v. 19. New York: Raven Press, 1982: 361-67.
10. Stern Y., Sano M., Mayeux R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology 1988: 38: 1837-41.
11. Sano M., Bell K., Marder K., Stricks D., Stern Y., Mayeux R. Safety and efficacy of oral physostigmine in the treatment of Alzheimer's disease. Clin Neuropharmacol 1993: 16: 61-69.
12. Levy A., Brandeis R., Treves T. et al. Transdermal physostigmine in the treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 1994: 8: 15-21.
13. Tune L., Brandt J., Frost JJ et al. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatr Scand Suppl 1991: 366: 61-65.
14. Wilson K., Bowen D., Francis P., Tyrrell P. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease. Br J Psychiatry 1991: 158: 558-62.
15. Summers WK, Majovski LV, Marsh GM, Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986: 315: 1241-45.
16. Davis KL, Thal LJ, Gamzu ER et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992: 327: 1253-59.
17. Farlow M., Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992: 268: 2523-29.
18. Knapp JM, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994: 271: 985-91.
19. Eagger SA, Levy R., Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991: 337: 989-92.
20. Wilcock GK, Scott M., Pearsall T., Neubauer K., Boyle M., Razay G. Galanthamine and the treatment of Alzheimer's disease. Int J Geriatr Psychiatry 1993: 8: 781-82.
21. Van-Duijn CM, Hofman A. Relation between nicotine intake and Alzheimer's disease. Br Med J 1991: 302: 1491-94.
22. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994: 13: 131-44.
23. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994: 13: 131-44.
24. Van-Duijn CM, Hofman A. Relation between nicotine intake and Alzheimer's disease. Br Med J 1991: 302: 1491-94.
25. Jones GM, Sahakian BJ, Levy R., Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory. Psychopharmacology (Berlin) 1992: 108: 485-94.
26. Schroder H., Giacobini E., Struble RG, Zilles K., Maclicke A. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol Aging 1991: 12: 259-62.
27. 3H] methylcarbamylcholine binding sites in the rat and human brain; relationship to functional nicotinic autoreceptors and alterations in Alzheimer's disease. Prog Brain Res 1989: 79: 345-52.
28. Sugaya K., Giacobini E., Chiapinelli VA. Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J Neurosci Res 1990: 27: 349-59.
29. Burke WJ, Chung HD, Huang JS et al. Evidence for retrograde degeneration of epinephrine neurons in Alzheimer's disease. Ann Neurol 1988: 24: 532-36.
30. Baker GB, Reynolds CP. Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata. Neurosci Lett 1989: 100: 335-39.
31. Chalmers DT, Dewar D., Graham DI, Brooks DN, McCulloch J. Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc Natl Acad Sci USA 1990: 87: 1352-56.
32. Lowe SL, Bowen DM, Francis PT, Neary D. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 1990: 38: 571-77.
33. Kowall NW, Beal MF. Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1991: 29: 162-67.
34. Blennow K., Wallin A., Gottfries CG et al. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging 1992: 12: 581-87.
35. Nazarali AJ, Reynolds GP. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cell Mol Neurobiol 1992: 12: 581-87.
36. Alhainen K., Helkala EL, Reinikainen K., Reikkinen P. The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1993: 5: 185-95.
37. Sherif F., Gottfries CG, Alafuzoff I., Oreland L. Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1992: 4: 227-40.
38. 3H]idazoxan binding sites (12 imidazoline sites) are increased in postmortem brains from patients with Alzheimer's disease. Neurosci Lett 1993: 160: 109-12.
39. Parnetti L., Reboldi GP, Santucci C. et al. Platelet MAO-B activity as a market of behavioural characteristics in dementia patients. Aging (Milano) 1994: 6: 201-7.
40. Finali G., Piccinilli M., Oliani C., Piccinin GL. L-deprenyl therapy improves verbal memory in amnesic Alzheimer's patients. Clin Neuropharmacol 1991: 14: 523-36.
41. Agnoli A., Fabbrini G., Fioravanti S., Martucci N. CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study. Eur Neuropsychopharmacol 1992: 2: 31-35.
42. Goad DL, Davis CM, Liem P., Fuselier C. et al. The use of selegiline in Alzheimer's patients with behavioural problems. J Clin Psychiatry 1991: 52: 342-45.
43. Dysken MW, Mendels J., Lewitt P. et al. Milacemide: a placebo-controlled study in senile dementia of Alzheimer's disease. J Am Geriatr Soc 1992: 40: 503-6.
44. Sunderland T., Molchan S., Lawlor S. et al. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. Int Psychogeriatr 1992 (4 suppl): 2: 291-309.
45. Bierer LM, Aisen PS, Davidson M., Ryan TM, Schmeidler J., Davis KL. A pilot study of clonidine plus physostigmine in AD. Dementia 1994: 5: 243-46.
46. Bierer LM, Aisen PS, Davidson M. et al. A pilot study of oral physostigmine plus yohimbine in patients with AD. Alzheimer Dis Assoc Disord 1993: 7: 98-104.
47. Repressa A., Duyckaerts C., Tremblay E., Hauw JJ, Ben-Ari Y. Is senile dementia of Alzheimer type associated with hippocampal plasticity Brain Res 1988: 457: 355-59.
48. Ingram DK, Spangler EL, Iijima S. et al. New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment. Ann NY Acad Sci 1994: 171: 16-32.
49. Greenamyre JT, Young AB. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 1989: 10: 593-602.
50. Choi DW, Rothmann SM. The role of glutamate neurotoxicity in hypoxic-ischaemic neuronal death. Ann Rev Neurosci 1990: P13: 171-82.
51. Randolph C., Roberts JW, Tierney MC et al. D-cycloserine treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 1994: 8: 198-205.
52. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic Multicentre Study. Br J Psychiatry 1990: 157: 894-901.
53. Matsubara E., Hirai S., Amari M. et al. Alpha-1-antichymotrypsin as a possible biochemical marker for AD. Ann Neurol 1990: 28: 561-67.
54. Brugge K., Katzman R., Hill LR, Hansen LA, Saitoh T. Serological alpha-1-antichymotrypsin in Down's Syndrome and Alzheimer's Disease. Ann Neurol 1992: 32: 193-97.
55. Griffin WS, Stanley LC, Ling C. et al. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer Disease. Proc Natl Acad Sci USA 1989: 86: 7611-15.
56. Bauer J., Ganter U., Strauss S. et al. The participation of interleukin-6 in the pathogenesis of AD. Res Immunol 1992: 143: 650-57.
57. Goldgaber D., Harris HW, Hla T. et al. Interleukin-1 regulates sythesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989: 86: 7606-10.
58. Altisiel L., Sperger K. Cytokines in AD. Prog Neuropsychopharmacol Biol Psychiatry 1991: 15: 481-95.
59. Haga S., Akai K., Ishii T. Demonstration of microglial cells in and around senile plaques in the AD: an immunochemical study using a novel monoclonal antibody. Acta Neuropathol 1989: 77: 195-200.
60. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C., Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995: 45: 51-55.
61. Rogers J., Kirby LC, Hempelman SR et al. Clinical trial of indomethacin in AD. Neurology 1993: 43: 1609-11.
62. Caporaso GL, Gandy SE, Buxbaum JD, Greengard P. Chloroquine inhibits intracellular degradation but not secretion of Alzheimer beta/A4 amyloid precursor protein. Proc Natl Acad Sci USA 1992: 89: 2252-56.
63. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987: 237: 1154-62.
64. Seiler M., Schwab ME. Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat. Brain Res 1984: 300: 33-39.
65. Dawbarn D., Allen SJ, Semenenko FM. Immunohistochemical localization of beta-nerve growth factor receptors in the forebrain of the rat. Brain Res 1988: 440: 185-89.
66. Allen SJ, Dawbarn D., Spillantini MG et al. Distribution of beta-nerve growth factor receptors in the human basal forebrain. J Comp Neurol 1989: 289: 626-40.
67. Batchelor PE, Armstrong DM, Blaker SN, Gage FH. Nerve growth factor receptor and choline acetyltransferase colocalization in neurons within the rat forebrain: response to fimbria-fornix transection. J Comp Neurol 1989: 284: 187-204.
68. Kordower JH, Gash DM, Bothwell M., Hersh L., Mufson EJ. Nerve growth factor receptor and choline acetyltransferase remain colocalized in the nucleus basalis (Ch4) of Alzheimer's patients. Neurobiol Aging 1989: 10: 67-74.
69. Hefti F., Mash DC. Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Neurobiol Aging 1989: 10: 75-87.
70. Dawbarn D., Allen SJ, Semenenko FM. Coexistence of choline acetyltransferase and nerve growth factor receptors in the rat basal forebrain. Neurosci Lett 1988: 94: 138-44.
71. Allen SJ, Dawbarn D., Wilcock GK. Morphometric immunochemical analysis of neurons in the nucleus basalis of Meynert in Alzheimer's disease. Brain Res 1988: 454: 275-81.
72. Hagg T., Manthorpe M., Vahlsing HL, Varon S. Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage. Exp Neurol 1988: 101: 303-12.
73. Hagg T., Fass-Holmes B., Vahlsing HL, Manthorpe M., Conner JM, Varon S. Nerve growth factor (NGF) reverses axotomy-induced decreases in choline acetyltransferase, NGF receptor and size of medial septum cholinergic neurons. Brain Res 1989: 505: 29-38.
74. Tuszynski MHUHS, Amaral DG, Gage FH. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 1990: 10: 3604-14.
75. Phillips HS, Hains JM, Armanini M., Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991: 7: 695-702.
76. Knüsel B., Beck KD, Winslow JW et al. Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J Neurosci 1992: 12: 4391-4402.
77. 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm (PD Sect) 1992: 4: 79-95.
78. Ebstein RP, Bennett ER, Sokoloff M., Shoham S. The effect of nerve growth factor on cholinergic cells in primary fetal striatal cultures: characterization by in situ hybridization. Dev Brain Res 1993: 73: 165-72.
79. Friden PM, Walus LR, Watson P. et al. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 1993: 259: 373-77.
80. Miller AD. Human gene therapy comes of age. Nature 1992: 357: 455-60.
81. Violette SM, Shashikant CS, Salbaum JM, Belting HG, Wang JC, Ruddle FH. Repression of the beta-amyloid gene in a Hox-3.1-producing cell line. Proc Natl Acad Sci USA 1992: 89: 3805-9.
82. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993: 261: 921-23.
83. Saunders AM, Schmader K., Breitner JC et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993: 342: 710-11.
84. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993: 11: 575-80.
85. Mayeux R., Stern Y., Ottman R. et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol 1993: 34: 752-54.